Anakinra to Prevent Post-infarction Remodeling

Phase 3

Completed

• Conditions: ST Segment Elevation Acute Myocardial Infarction
• Interventions: Drug: Placebo; Drug: Anakinra

• Registration Number: NCT00789724
• Lead Sponsor: Virginia Commonwealth University

Brief Summary

Thousands of patients die daily from early and late complications of a heart attack (acute myocardial infarction, AMI). Patients surviving AMI remain at high risk of death from adverse cardiac remodeling (dysfunction and enlargement of the heart) leading to heart failure (weakening of the heart).

Current interventions proven to reduce adverse remodeling and progression to heart failure include early reperfusion (restoring blood flow to the heart muscle) and long-term use of medicines that block the effects of hormones (such as angiotensin II, norepinephrine and aldosterone) involved in adverse remodeling. Despite these treatments, however, many patients continue to develop heart failure within 1 year of AMI. These patients are at very high risk of death.

Numerous changes occur in the hearts of patients after AMI that lead to adverse remodeling. Ischemia (lack of oxygen) and infarction (cell damage) lead to increased interleukin-1 (IL-1) production in the heart. IL-1 plays a critical role in adverse cardiac remodeling by coordinating the inflammatory pathway (leading to wound healing) and apoptotic pathway (leading to cell death).

In opposition to IL-1 activity, the human body produces a natural IL-1 receptor antagonist that blocks the effects of IL-1. The drug form of this IL-1 receptor antagonist (anakinra) is currently FDA approved for the treatment of rheumatoid arthritis, an inflammatory disease characterized by excessive IL-1 activity. Experimental studies show that anakinra is able to prevent cardiac remodeling and improve survival in mice after AMI.

We hypothesize that anakinra will show similar benefits in human patients by preventing adverse remodeling and heart failure after AMI.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-11
• Study First Submitted: 2008-11-11
• Study First Submitted QC: 2008-11-12
• Study First Posted: 2008-11-13
• Primary Completion: 2009-08
• Study Completion: 2009-08
• Results First Submitted: 2010-07-30
• Results First Submitted QC: 2010-07-30
• Results First Posted: 2010-08-24
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-24
• Last Update Posted: 2017-11-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Age >18 years
• Acute (<24 hours) onset of chest pain
• New or presumably new ST elevation on ECG
• Planned coronary angiography for percutaneous revascularization

Read More

Exclusion Criteria

• Inability to give informed consent
• Late presentation (>24 hours)
• Unsuccessful revascularization or urgent coronary bypass surgery
• Hemodynamic instability
• End-stage congestive heart failure (AHA/ACC stage C/D, NYHA class IV)
• Preexisting severe LV dysfunction (LVEF<20%) or severe valvular disease
• Severe asthma
• Pregnancy ( pre-enrollment pregnancy test)
• Contraindications to cardiac MRI or cardiac angiography
• Severe coagulopathy (INR>2.0, Platelet count<50,000/mm3)
• Severe renal insufficiency (creatinine clearance <30 ml/min/m2)
• Recent (<14 days) use of anti-inflammatory drugs (NSAIDS excluded)
• Chronic inflammatory disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	0.67 ml of NaCl 0.9% solution
Anakinra	Anakinra	Anakinra 100 mg given daily by subcutaneous injection for 14 days

Primary Outcome Measures

Name	Time	Method
Difference Between the Anakinra Arm and Placebo Arm in Change in End-systolic Volume Indices From Baseline to Follow up Exam 10-14 Weeks Later at Cardiac Magnetic Resonance Imaging.	10-14 weeks

Trial Locations

Locations (1)

Virginia Commonwealth University; 🇺🇸 Richmond, Virginia, United States